Sign In
Buy OKYO
$1.55
+0.0700 (+4.73%)
At Close: Jul 24, 2026
TSMC reports record June revenue, second quarter sales top guidance
05:50am, Monday, 13'th Jul 2026
Taiwan Semiconductor Manufacturing Co (ADR) (NYSE:TSM) reported record June revenue of NT$442.7 billion (about US$13.2 billion), as strong demand for its...
OKYO Pharma advances toward Phase 3 FDA trial - ICYMI
10:12am, Saturday, 11'th Jul 2026
OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week reported positive feedback from its Type D meeting with the US Food and Drug Administration (FDA), providing greater regulatory clarity as the company a
OKYO Pharma advances toward Phase 3 FDA trial - ICYMI
06:00am, Saturday, 11'th Jul 2026
OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week reported positive feedback from its Type D meeting with the US Food and Drug Administration (FDA), providing...
Forte Biosciences shares surge after positive phase 1b vitiligo results
09:26am, Thursday, 09'th Jul 2026
Forte Biosciences (NASDAQ:FBRX) shares jumped about 55% after the company reported positive phase 1b clinical trial results for FB102, an investigational...
FTSE 100 Live: Stocks called higher as Trump signals Iran ready for talks
03:19am, Thursday, 09'th Jul 2026
FTSE 100 Live pre-open Blue-chip stocks in London and mainland Europe are set to rebound on Thursday after reports that the US and Iran could agree a new...
Nasdaq bucks market selloff as US-Iran tensions push oil higher
12:18pm, Wednesday, 08'th Jul 2026
4:15pm: Oil surge pressures Dow, S&P 500 US stocks finished mixed on Wednesday as a jump in oil prices fueled inflation concerns and weighed on investor...
OKYO Pharma reports FDA feedback, advances urcosimod into Phase 3 trial for neuropathic corneal pain
08:35am, Wednesday, 08'th Jul 2026
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has received positive feedback from a US Food and Drug Administration Type D meeting that supports advancing its investigational therapy urcosimod into
LONDON and NEW YORK, July 08, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropa
OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium
07:00am, Tuesday, 07'th Jul 2026
LONDON and NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropat
OKYO Pharma expands scientific advisory board with cornea expert - ICYMI
08:02am, Saturday, 23'rd May 2026
OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week announced the appointment of Dr. Marta Sacchetti to its scientific advisory board as the company advances development of its lead ophthalmic candidate t
OKYO Pharma expands scientific advisory board with cornea expert - ICYMI
04:00am, Saturday, 23'rd May 2026
OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week announced the appointment of Dr. Marta Sacchetti to its scientific advisory board as the company advances...
What Makes OKYO Pharma (OKYO) a New Buy Stock
01:01pm, Wednesday, 20'th May 2026
OKYO Pharma (OKYO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
FTSE 100 Live: Stocks lose early gains as UK jobs market cools, IG and Currys surge
12:05pm, Tuesday, 19'th May 2026
FTSE 100 up 11 points at 10,335 UK jobs data weakens, unemployment back to 5% IG Group, Diploma, Currys, Dr Martens, SSP, Cranswick among reporters ...
OKYO Pharma adds ophthalmology specialist Marta Sacchetti to Scientific Advisory Board
10:00am, Tuesday, 19'th May 2026
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has expanded its Scientific Advisory Board with the appointment of Dr. Marta Sacchetti as the company continues advancing its clinical programs in neuro
OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD
07:00am, Tuesday, 19'th May 2026
Dr. Sacchetti brings international expertise in clinical and translational research on ocular inflammatory and degenerative disease OKYO's introduction to the broader ophthalmology community at ASCRS
